Li Tianhang, You Qinqin, Zhang Shiwei, Li Rushuai, Xie Shangxun, Li Danyan, Ai Shuyue, Yang Rong, Guo Hongqian
Department of Urology, Affiliated Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
Department of Urology, Zhongda Hospital, Southeast University, Nanjing, China.
iScience. 2024 Apr 3;27(5):109657. doi: 10.1016/j.isci.2024.109657. eCollection 2024 May 17.
F-FDG PET/MRI shows potential efficacy in the diagnosis of bladder cancer (BLCA). However, the performance of F-FDG PET/MRI in staging and neoadjuvant therapy (NAT) response evaluation for BLCA patients remains elusive. Here, we conduct this study to evaluate the performance of F-FDG PET/MRI and its derived parameters for tumor staging and NAT response prediction in BLCA. Forty BLCA patients were retrospectively enrolled to evaluate the performance of F-FDG PET/MRI in staging and NAT response prediction in BLCA. The feasibility of using 18F-FDG PET/MRI-related parameters for tumor staging and NAT response evaluation was also analyzed. In conclusion, F-FDG PET/MRI is found to show good performance in the BLCA staging and NAT response prediction. Moreover, ΔSUVmean is an efficacious candidate parameter for NAT response prediction. This study highlights that F-FDG PET/MRI is a promising imaging approach in the clinical diagnosis and treatment for BLCA.
F-FDG PET/MRI在膀胱癌（BLCA）诊断中显示出潜在疗效。然而，F-FDG PET/MRI在BLCA患者分期及新辅助治疗（NAT）反应评估中的表现仍不明确。在此，我们开展本研究以评估F-FDG PET/MRI及其衍生参数在BLCA肿瘤分期及NAT反应预测中的表现。回顾性纳入40例BLCA患者，以评估F-FDG PET/MRI在BLCA分期及NAT反应预测中的表现。还分析了使用18F-FDG PET/MRI相关参数进行肿瘤分期及NAT反应评估的可行性。总之，发现F-FDG PET/MRI在BLCA分期及NAT反应预测中表现良好。此外，ΔSUVmean是NAT反应预测的有效候选参数。本研究强调F-FDG PET/MRI在BLCA临床诊断和治疗中是一种有前景的成像方法。
Zotero 插件
